Artiva Biotherapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 29, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 24, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 21, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 13, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 16, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 10, 2026.
NASDAQ
RA Capital Management and affiliated entities report significant purchases of Artiva Biotherapeutics common stock, increasing their beneficial ownership.
NASDAQ
RA Capital Management has reported significant open-market purchases of Artiva Biotherapeutics common stock.
NASDAQ
RA Capital Management has significantly increased its beneficial ownership in Artiva Biotherapeutics through a series of open-market common stock purchases.
NASDAQ
GC Corp. and its subsidiary GC Cell Corporation acquired a combined 1,432,291 shares of Artiva Biotherapeutics, Inc. at $11.52 per share.
NASDAQ
SVP of Research and Development Heather Raymon sold 3,095 shares of Artiva Biotherapeutics to satisfy tax withholding requirements.
NASDAQ
Chief Tech Operations Officer Christopher Horan sold 7,002 shares of Artiva Biotherapeutics to satisfy tax withholding requirements.
NASDAQ
Artiva Biotherapeutics COO Jennifer Bush sold 8,790 shares at an average price of $9.01 to satisfy tax withholding requirements following RSU vesting.
NASDAQ
Artiva Biotherapeutics Chief Medical Officer Subhashis Banerjee sold 7,037 shares to cover tax liabilities following the vesting of restricted stock units.
NASDAQ
Artiva Biotherapeutics CEO Fred Aslan sold 27,116 shares at an average price of $9.00 to satisfy tax withholding requirements.
NASDAQ
Artiva Biotherapeutics executive Gines Diego Miralles reports the acquisition of restricted stock units and stock options, detailing grant details and vesting schedules.
NASDAQ
RA Capital Management has acquired 6.5 million shares and 2.17 million pre-funded warrants in Artiva Biotherapeutics.
NASDAQ
Artiva Biotherapeutics Director Elaine K. Sorg was granted 27,500 stock options with an exercise price of $4.15, vesting over three years.
NASDAQ
Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, received a restricted stock unit award and sold shares to cover tax obligations.
NASDAQ
Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, reported an acquisition of 117,300 restricted stock units and a disposition of 2,187 shares for tax purposes.
NASDAQ
Artiva Biotherapeutics' COO, Jennifer Bush, reported the acquisition of 117,300 shares via a restricted stock unit award and the disposition of 3,515 shares for tax obligations.
NASDAQ
Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, was granted 102,000 restricted stock units under the company's 2024 Equity Incentive Plan.
NASDAQ
Artiva Biotherapeutics' President and CEO, Fred Aslan, reported the acquisition of 366,850 restricted stock units and the disposition of 14,600 shares for tax obligations.
NASDAQ
Artiva Biotherapeutics' President and CEO, Fred Aslan, sold 3,187 shares of common stock at $6 per share, executed under a pre-arranged 10b5-1 trading plan.
NASDAQ
Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, exchanged employee stock options for 67,253 restricted stock units.
NASDAQ
Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, exchanged 107,157 stock options for 107,156 Restricted Stock Units.
NASDAQ
Artiva Biotherapeutics' COO, Jennifer Bush, exchanged existing employee stock options for 84,877 restricted stock units on December 12, 2025.
NASDAQ
Artiva Biotherapeutics' President and CEO, Fred Aslan, exchanged employee stock options for 869,136 restricted stock units on December 12, 2025.
NASDAQ
Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, reported a disposition of 1,375 common shares for tax obligations related to RSU vesting.
NASDAQ
Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, disposed of 1,899 shares of common stock to cover tax obligations related to restricted stock unit vesting.